INmune Bio (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, this morning announced that various management team members including CEO Raymond J. Tesi, CFO David Moss and chief scientific officer Professor Mark Lowdell will ring the NASDAQ closing bell on Tuesday, April 9, 2019. The closing bell ceremony will be streamed live from the NASDAQ MarketSite Tower in New York starting at 3:45 PM ET. “On behalf of the INmune Bio management team and our board of directors, we are honored to celebrate our recent IPO by ringing the NASDAQ closing bell,” INmune Bio CEO Raymond J. Tesi stated in the news release. “Our successful IPO has provided us with financing to pursue the continued advancement of our immunotherapy programs that harness the power of the innate immune system in multiple, critical clinical trials. Our team will continue to focus on developing innovative treatment alternatives to fight cancer and neurodegenerative diseases.”
To view the live broadcast, visit http://nnw.fm/3fPbZ
To view the full press release, visit http://nnw.fm/tA45Y
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer (“NK”) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid derived suppressor cells (“MDSC”), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. For more information, visit the company’s website at www.INmuneBio.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
